Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT.

J Exp Med. 1995 Aug 1;182(2):501-9.

2.

Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.

Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M.

Lab Invest. 1996 Jan;74(1):33-42.

PMID:
8569195
4.
5.

Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.

Saifuddin M, Ghassemi M, Patki C, Parker CJ, Spear GT.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):829-37.

PMID:
7527236
6.

Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Schmitz J, Zimmer JP, Kluxen B, Aries S, Bögel M, Gigli I, Schmitz H.

J Clin Invest. 1995 Sep;96(3):1520-6.

8.

Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.

Nakamura M, Okada H, Sasaki H, Yoshida K, Kamada M, Okada N, Terada M, Ohno T.

Microbiol Immunol. 1996;40(8):561-7.

PMID:
8887350
9.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608
10.
11.

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.

Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1884-91.

PMID:
8759358
12.
13.

HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.

Marschang P, Gürtler L, Tötsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP.

AIDS. 1993 Jul;7(7):903-10.

PMID:
7689323
14.

Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.

Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, Spear GT.

J Immunol. 1996 Aug 15;157(4):1791-8.

PMID:
8759769
15.

K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.

Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M.

Int J Cancer. 2001 Sep;93(6):848-54.

16.

Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.

Yuan FF, Bryant JA, Fletcher A.

Immunol Cell Biol. 1995 Feb;73(1):66-72.

17.

Correction of the PNH defect by GPI-anchored protein transfer.

Sloand EM, Maciejewski JP, Dunn D, Moss J, Brewer B, Kirby M, Young NS.

Blood. 1998 Dec 1;92(11):4439-45.

19.
20.

Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria.

Shichishima T, Terasawa T, Hashimoto C, Ohto H, Takahashi M, Shibata A, Maruyama Y.

Blood. 1993 Apr 1;81(7):1855-62.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk